Sanofi (SNY)
(Real Time Quote from BATS)
$50.86 USD
+0.43 (0.85%)
Updated Jul 24, 2024 02:52 PM ET
3-Hold of 5 3
A Value D Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SNY 50.86 +0.43(0.85%)
Will SNY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SNY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SNY
The Zacks Analyst Blog Highlights Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences
Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?
SNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
Novavax's (NVAX) Shares Surge 211% YTD: Time to Buy the Stock?
Is AstraZeneca (AZN) a Portfolio Must-Have Pre-Q2 Earnings?
Other News for SNY
Sanofi call volume above normal and directionally bullish
Sanofi’s Dupixent: A New Era in COPD Treatment
Merck RSV therapy succeeds in infants in challenge to Sanofi, Astra
Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking
AstraZeneca, Sanofi And Other Pharma Giants Pursue Chinese Deals Despite Rising US-China Strife